Sanofi/Aventis Merger Would Prevent Plavix-Style Profit-Sharing Agreements, CEO Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi downplays Aventis' sales force as a major reason for merging with its French neighbor. Sanofi has nine late-stage products, including the smoking cessation/obesity agent rimonabant and antiarrhythmic dronedarone.
You may also be interested in...
Sanofi Plans To Add Two NMEs To Phase III In 2004, Bringing Total To Nine
Antidepressant saredutant and hyponatremia agent SR 121463 are ready to proceed to final stage of development after successful Phase IIb results. Combined with merger target Aventis, Sanofi's current total would be 12 novel Phase III agents, rivaled only by Pfizer.
Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.